Follow the Metadata
SAS, Medidata Partner
The leading biostatistical house and a top EDC vendor say they have a better way to move clinical data toward analysis.
The software that ordinary people prefer is getting simpler. Easier. And it’s increasingly running not on a desktop computer, like Microsoft Word, but online. Last year, the web ratings firm comScore estimated in this Powerpoint deck that, in the U.S., an impressive 78 percent of users had tried a small, internet program called a widget. Widgets are apparently more popular than watching online video, the firm says. Now the trend is starting to ripple through the business world. One of the heaviest pieces of iron in the industry—SAS Drug Development—is now available in an online mode. In its so-called “on demand” offering, SAS hosts the program, and users log on via the internet. SAS’s goal is to have customers up and running on the system in a month. Life science firms’ IT departments need not be involved in setting up SAS Drug Development in this approach. But unlike widgets for consumers,…more...
Does the pharmaceutical industry need to rethink the management of drug safety data and pharmacovigilance? A few companies already are. That was clear at this year’s annual Society For Clinical Data…more...
Could the pharmaceutical industry manage clinical data more intelligently, using software to go toe to toe with Steve Nissen of the Cleveland Clinic? Would such tools ensure more consistent communications with…more...
How fast can your company analyze its clinical data? If a medical journal says your data are incomplete on a Thursday morning, is the turnaround time for your response a) one…more...
Yesterday, in a separate story, we talked with consultant George Laszlo about clinical data repository (CDR) functionality and terminology. This article is more forward-looking, and mentions some choices and long-term benefits for a CDR. Laszlo thinks the industry should ponder where clean clinical trial data should live. How easily will ad hoc reports be run off that…more...
Is the data-handling part of the pharmaceutical industry being inexact in its use of some key terms? Is it preparing intelligently for the future? Consultant George Laszlo wonders. On the terminology front, he says sheer sloppiness is obscuring some of the most urgent priorities. His question: where exactly should the industry clean all that clinical data it’s…more...
A key committee in the U.S. House of Representatives passed a weaker version of user fee and drug safety legislation, dropping a requirement for FDA analysis of post-marketing data and avoiding a showdown over tighter rules about promoting drugs after they are launched as products. The legislation would mandate a database for clinical trial results. SAS recently…more...
INC Research, a contract research organization (CRO), has officially implemented its Trusted Process in all of its current clinical trial programs. The Trusted Process is a series of phases that proactively lead customers through their drug and device development programs with repeatable and measurable methodology. As a result, INC Research minimizes trial risk factors and customers experience…more...
The leading biostatistical house and a top EDC vendor say they have a better way to move clinical data toward analysis.
Obsolescence? Or greater prominence? The recent conference in Florida explored how clinical data managers should prepare for a landscape with more technology.
In a wide ranging conversation, John Murray talks about where the industry is headed and what lies ahead for electronic data capture.
The founder of a SAS-based clinical data management system talks about clinical data management and standards.
Organizations
Conferences
Info & Opinion
© 2010 ClinPage. All Rights Reserved.